Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113667 - 113667
Опубликована: Март 1, 2025
Язык: Английский
Molecular Cancer, Год журнала: 2025, Номер 24(1)
Опубликована: Май 7, 2025
Cancer immunotherapy, encompassing both experimental and standard-of-care therapies, has emerged as a promising approach to harnessing the immune system for tumor suppression. Experimental strategies, including novel immunotherapies preclinical models, are actively being explored, while established treatments, such checkpoint inhibitors (ICIs), widely implemented in clinical settings. This comprehensive review examines historical evolution, underlying mechanisms, diverse strategies of cancer highlighting its applications ongoing advancements. The delves into essential components anticancer immunity, dendritic cell activation, T priming, surveillance, addressing challenges posed by evasion mechanisms. Key immunotherapeutic vaccines, oncolytic viruses, adoptive transfer, ICIs, discussed detail. Additionally, role nanotechnology, cytokines, chemokines, adjuvants enhancing precision efficacy were explored. Combination particularly those integrating immunotherapy with radiotherapy or chemotherapy, exhibit synergistic potential but necessitate careful management reduce side effects. Emerging factors influencing outcomes, heterogeneity, gut microbiota composition, genomic epigenetic modifications, also examined. Furthermore, molecular mechanisms therapeutic resistance analyzed, focus on contributions noncoding RNAs alterations, along innovative intervention strategies. emphasizes recent advancements, particular attention biomarker-driven approaches aimed at optimizing patient prognosis. Challenges immunotherapy-related toxicity, limited solid tumors, production constraints highlighted critical areas future research. Advancements personalized therapies delivery systems proposed avenues enhance treatment effectiveness accessibility. By incorporating insights from multiple disciplines, this aims deepen understanding application ultimately fostering more effective accessible solutions.
Язык: Английский
Процитировано
1
Biomaterials, Год журнала: 2024, Номер 314, С. 122856 - 122856
Опубликована: Сен. 28, 2024
Язык: Английский
Процитировано
6
Nanoscale, Год журнала: 2024, Номер 16(38), С. 17699 - 17722
Опубликована: Янв. 1, 2024
This review explores recent advances in the development of cancer immunotherapy using nanoparticles for tumor vaccine, stimulating specific T cells, and delivering immuno-activation modulatory agents to activate cytotoxic cells.
Язык: Английский
Процитировано
4
Small, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 6, 2024
Abstract Subunit vaccines, significant in next‐generation vaccine development, offer precise targeting of immune responses by focusing on specific antigens. However, this precision often comes at the cost eliciting strong and durable immunity, posing a great challenge to design. To address limitation, recent advancements nanoparticles (NPs) are utilized enhance antigen delivery efficiency boost efficacy. This review examines how physicochemical properties NPs influence various stages response during analyzes different NP types contribute activation performance. It then explores unique characteristics mechanisms these NPs, along with their advancements, highlights application subunit vaccines infectious diseases cancer. Finally, it discusses challenges NP‐based development proposes future directions for innovation promising field.
Язык: Английский
Процитировано
4
EBioMedicine, Год журнала: 2024, Номер 111, С. 105491 - 105491
Опубликована: Дек. 6, 2024
Язык: Английский
Процитировано
3
International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 181 - 197
Опубликована: Янв. 1, 2025
Abstract: The microenvironment tends to be immunosuppressive during tumor growth and proliferation. Immunotherapy has attracted much attention because of its ability activate tumor-specific immune responses for killing. cyclic GMP-AMP synthase-stimulator interferon genes (cGAS-STING) pathway is an innate that activates antitumor immunity by producing type I interferons. Cyclic dinucleotides (CDNs), produced cGAS sensing cytoplasmic abnormal DNA, are major intermediate activating molecules in the STING pathway. Nowadays, CDNs their derivatives have widely worked as powerful agonists immunotherapy. However, clinical translation hindered negative electrical properties, sensitivity hydrolytic enzymes, systemic toxicity. Recently, various CDN delivery systems made significant progress addressing these issues, either through monotherapy or combination with other treatment modalities. This review details recent advances CDNs-based pharmaceutical development strategies enriching at sites Keywords: dinucleotides, stimulator pathway, immunotherapy
Язык: Английский
Процитировано
0
Nanomaterials, Год журнала: 2025, Номер 15(2), С. 122 - 122
Опубликована: Янв. 16, 2025
Nano-oncologic vaccines represent a groundbreaking approach in the field of cancer immunotherapy, leveraging unique advantages nanotechnology to enhance effectiveness and specificity treatments. These utilize nanoscale carriers deliver tumor-associated antigens immunostimulatory adjuvants, facilitating targeted immune activation promoting robust antitumor responses. By improving antigen presentation localizing within tumor microenvironment, nano-oncologic can significantly increase efficacy particularly when combined with other treatment modalities. This review highlights mechanisms through which operate, their potential overcome existing limitations treatment, ongoing advancements design. Additionally, it discusses delivery approach, such as EPR effects, pH response, ultrasonic magnetic response. The combination therapy effects photothermal therapy, radiotherapy, or checkpoint inhibitors are also discussed. Overall, hold great promise for changing landscape advancing personalized medicine, paving way more effective therapeutic strategies tailored individual patient needs.
Язык: Английский
Процитировано
0
ACS Nano, Год журнала: 2025, Номер unknown
Опубликована: Янв. 16, 2025
Tumor-specific T cells play a vital role in potent antitumor immunity. However, their efficacy is severely affected by the spatiotemporal orchestration of antigen-presentation as well innate immune response dendritic (DCs). Herein, we develop minimalist nanovaccine that exploits dual immunofunctional polymeric nanoplatform (DIPNP) to encapsulate ovalbumin (OVA) via electrostatic interaction when nanocarrier serves both STING agonist and adjuvant DCs. In vitro results reveal induces activation facilitating interferon regulatory factor 3 phosphorylation block poly 18-crown-6-yl methacrylate (P18C6MA) mediated K+ perturbation cascade with endoplasmic reticulum stress, stimulates DC maturation Toll-like receptor 4 primary amine. vivo studies indicate smart dramatically inhibits tumor growth long-term memory B16-OVA EG7-OVA models. After combination programmed death ligand-1 antibody (aPD-L1), mice survival rate notably prolonged. addition, DIPNP forms personalized after resected autologous cell membranes decoration high activity homologous distant model. The rational design provides inspiration for construction nanocarriers.
Язык: Английский
Процитировано
0
Journal of Materials Chemistry B, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
The primary objective of neoantigen vaccines is to elicit a robust anti-tumor immune response by generating neoantigen-specific T cells that can eradicate tumor cells. Despite substantial advancements in personalized prediction using next-generation sequencing, machine learning, and mass spectrometry, challenges remain efficiently expanding cell populations vivo. This challenge impedes the widespread clinical application vaccines. Nanovector-based delivery systems have emerged as promising solutions this challenge. These nanovectors offer several advantages, such enhanced stability, targeted intracellular delivery, sustained release, improved antigen-presenting (APC) activation. Notably, they effectively deliver various vaccine formulations (DC cell-based, synthetic long peptide (SLP)-based or DNA/mRNA-based) APCs cells, thereby activating both CD4+ CD8+ ultimately induces specific response. review focuses on recent innovations vectors. We aim identify optimal design parameters for vectors tailored different types, with an emphasis enhancing microenvironment stimulating production cytotoxic By maximizing potential these systems, we accelerate translation nanovaccines advance cancer immunotherapy.
Язык: Английский
Процитировано
0
Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 5, 2025
Язык: Английский
Процитировано
0